FierceBiotechOriginal article
{"a":[{"_":"AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates","$":{"href":"/biotech/astrazeneca-execs-very-confident-homegrown-adcs-despite-scrapping-2-candidates","hreflang":"en"}}]}
negativeADC pipeline candidatesNeutral
AI Analysis
Summary
AstraZeneca discontinued two antibody-drug conjugate candidates from its in-house pipeline due to clinical underperformance, though executives remain confident in the remaining ADC portfolio.
Outcome Details
Two ADC candidates scrapped due to underperformance in clinical trials
Importance:4/10
Sentiment:
0.10
ADCpipelineclinical_failuredrug_development
Related Companies
Read the original article
Published by FierceBiotech on July 27, 2026 5:35 AM
